NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1)

NovoCure Ltd. defeated claims that the oncology company misled investors about results of a clinical trial testing broader use of its brain and lung cancer therapy ahead of a record stock drop, a federal judge ruled.

The investor’s allegations were “at most” that the clinical trial should’ve had a different design or that their interpretation of the data was superior to that made by NovoCure and executives, Judge Gregory H. Woods said for the US District Court for the Southern District of New York. And lead plaintiff Clendon T. Rice didn’t adequately allege the level of intent to carry ...